Immunomediated Diseases and Innovative Therapies

Overview

The Immunomediated Diseases and Innovative Therapies is an heterogeneous area composed by both translational and clinical research groups which cover fields such as immunology, respiratory and systemic diseases, pharmacology, molecular diagnosis, heart repair, reumatology and advanced therapies. Its main strength derives precisely from this heterogeneity and the complementarity of the scientific interests and expertise of the different groups, many of which are currently joining efforts and synergizing in a variety of collaborative research projects.

Publications

214

total

1,338.943

impact factor

6.257

average impact factor

Group Leader: Jordi Barquinero Mañez

team

group-zoom

zoom

group-download

download

In relation with the project of a gene editing strategy to correct genetic defects in liver cells for metabolic diseases we have developed the molecular tools necessary for this correction in a model of mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) and we have demonstrated that they work in vitro, which is a prerequisite to test the strategy in the murine model of the disease. To this end we will use conventional adenoassociated vectors (AAVs) in combination with polymeric nanoparticles that are being developed in a collaboration with the group of Dr. S. Borrós (Institut Químic de Sarrià). Also, in collaboration with the group of Dr. F. Munell (Pediatric Neurology), our group has received funding for a research project aimed at developing a novel preclinical in vivo gene therapy approach to treat congenital muscular dystrophy type 1A (MCD1A), a progressive and orphan genetic disease which represents about 40% of all congenital muscular dystrophies.